Not registered yet? Please contact our project manager Vanessa Köhler.

Newsroom

Project News

This section keeps you updated on any major development throughout the course of the TIMESPAN project.

Project News

  • 12 June 2024

    Diabetes Awareness Week #2

    It’s #DiabetesWeek! We would like to raise awareness, backed by science and highlight scientific articles from TIMESPAN members. Read our first post here.
    A recent study in renowned journal Diabetes Research and Clinical Practice examined the effects of ADHD and ADHD treatment on glycemic management in type 1 diabetes.

    Conducting a systematic review and meta-analysis of observational studies, researchers found that mean HbA1c levels were significantly higher in T1D individuals with ADHD compared to those without ADHD. The rates of suboptimal HbA1c levels, hospitalization, diabetic ketoacidosis, and hypoglycemia were all substantially higher in T1D individuals with ADHD than those without ADHD. No difference was found in mean HbA1c between those who received ADHD treatment and those who did not.

    The authors concluded that identifying and addressing ADHD symptoms in T1D can improve glycemic management, and help prevent acute diabetes-related complications.

    Read the full publication here: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00049-4/

  • 10 June 2024

    Diabetes Awareness Week #1

    It’s #DiabetesWeek! A recent study in nature medicine examined the link between maternal diabetes mellitus and ADHD.
    Analyzing 3.6 million mother-child pairs, researchers found a small-to-moderate risk of ADHD in children exposed to maternal diabetes mellitus. The association between gestational diabetes mellitus and ADHD is unlikely to be causal.
    This finding contrast with previous studies, which reported substantially higher risk estimates, and underscores the need to reevaluate the precise roles of hyperglycemia and genetic factors in the relationship between MDM and ADHD.

    The study is open access via: https://doi.org/10.1038/s41591-024-02917-8

  • 14 May 2024

    Paper awarded Publication of the Year!

    🏆 CONGRATS! Isabell Brikell has been awarded the “Publication of the Year” prize by the Department of Global Public Health and Primary Care (IGS), University of Bergen (UiB). We’d like to extend this congratulations to Lin Li and Honghui Yao, who contributed equally to the paper.
    The winning publication is titled “ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases.”
    Read the paper here.

    Special congrats also to Kari Klungsøyr and Zheng Chang, as well as to all authors. As always, science is a group effort!

  • 16 April 2024

    TIMESPAN’s 4th General Assembly Meeting

    🌟 Reflecting on an important event for TIMESPAN! 🧠
    Last week, we convened for our fourth General Assembly Meeting in Copenhagen, Denmark, where we engaged in in-depth discussions covering our different work packages.
    A highlight ✨ was our posterwalk, where TIMESPAN’s Early Career Researchers presented their work and received valuable feedback.

    It was an inspiring meeting filled with insightful discussions and strategic planning for the future of our project.

    The dedication and collaboration of our international team continues to drive our project forward.

    A huge thank you to everyone who participated and contributed to making this meeting a success! Onward and upward! 💪

  • 8 April 2024

    Article in nature medicine: Maternal diabetes and risk ofattention-deficit/hyperactivity disorderin offspring in a multinational cohortof 3.6 million mother–child pairs

    Many TIMESPAN members have contributed to this multinational cohort study with linked mother–child pairs data in Hong Kong, New Zealand, Taiwan, Finland, Iceland, Norway and Sweden to evaluate associations between maternal diabetes mellitus (MDM) and ADHD. The team studied over 3.6 million mother-child pairs and showed that children who were born to mothers with any type of diabetes during pregnancy had a higher risk of ADHD than unexposed children (pooled hazard ratio (HR) = 1.16, 95% confidence interval (CI) = 1.08-1.24).

    However, siblings with discordant exposure to GDM in pregnancy had similar risks of ADHD (pooled HR = 1.05, 95% CI = 0.94-1.17), suggesting potential confounding by unmeasured, shared familial factors.
    The findings indicate that there is a small-to-moderate association between MDM and ADHD.

    Read the full paper here: https://doi.org/10.1038/s41591-024-02917-8

  • 4 April 2024

    Upcoming: TIMESPAN’s 4th GA Meeting

    Packed your suitcases and prepared all slides, yet? It’s less than a week until the TIMESPAN consortium meets again in-person, and for our colleagues who can’t make it to beautiful Copenhagen, there will be a hybrid option. During our 4th General Assembly Meeting, we’ll be discussing the project’s progress, its achievements so far, and plan ahead for the year to come.

  • 3 April 2024

    ART-CARMA enrolled the 200th patient

    The ART-CARMA team have now enrolled 200 participants into the study! A huge thank you to the data collection teams in both London and Barcelona and to all of our participants!

    Follow KCL’s ADHD RemoteTech team and TIMESPAN on X (formerly Twitter)!

  • 2 April 2024

    New paper: Associations between ADHD genetic liability and ICD-10 medical conditions in adults.

    In a Phenome-Wide Association Study (PheWAS), using data from the Estonian Biobank and genetic risk scores related to ADHD, this study found strong links with chronic obstructive pulmonary disease (COPD), obesity, and Type-2 diabetes.

    The article, titled “Associations between attention-deficit hyperactivity disorder genetic liability and ICD-10 medical conditions in adults: utilizing electronic health records in a Phenome-Wide Association Study” is authored by Ellis Haan, Kristi Krebs, Urmo Võsa, Isabell Brikell, Henrik Larsson, Kelli Lehto and the Estonian Biobank Research Team.

  • 12 March 2024

    New paper: ADHD-medication linked to reduced mortality

    A recent study published in JAMA by Lin Li et al. titled “ADHD Pharmacotherapy and Mortality in Individuals With ADHD” researchers also from TIMESPAN reveals a correlation between ADHD medication usage and a decreased likelihood of premature death. The findings suggest that the risk of death from unnatural causes, such as accidents and overdoses, may be reduced by 25% with ADHD medication.

    The study showed that there is a link between initiation of medication and a lower risk of death. “This was true regardless of the cause of death, but the risk of dying from unnatural causes, such as alcohol and drug overdose, decreased the most. The association was not as strong for the risk of dying from natural causes as physical health conditions,” says Lin Li, postdoctoral researcher at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet and first author of the study.

  • 22 February 2024

    New paper in Nature Reviews Disease Primers: Attention-deficit/hyperactivity disorder

    In this comprehensive Nature review by Stephen V. Faraone, Mark A. Bellgrove, Isabell Brikell, et al., three authors—Stephen Faraone, Isabell Brikell and Catharina A. Hartman—were supported by TIMESPAN. Congrats team!

    Key facts:

    • Attention-deficit/hyperactivity disorder is a common neurodevelopmental condition that affects children and adults worldwide.
    • ADHD has a predominantly genetic aetiology that involves common and rare genetic variants.
    • Some environmental correlates of the disorder have been discovered but causation has been difficult to establish.
    • The heterogeneity of the condition is evident in the diverse presentation of symptoms and levels of impairment, the numerous co-occurring mental and physical conditions, the various domains of neurocognitive impairment, and extensive minor structural and functional brain differences.
    • The diagnosis of ADHD is reliable and valid when evaluated with standard diagnostic criteria.
    • Curative treatments for ADHD do not exist but evidence-based treatments substantially reduce symptoms and/or functional impairment.
    • Medications are effective for core symptoms and are usually well tolerated.
    • Some non-pharmacological treatments are valuable, especially for improving adaptive functioning.
    • Clinical and neurobiological research is ongoing and could lead to the creation of personalized diagnostic and therapeutic approaches for this disorder.

    Read the full publication here.

  • 30 January 2024

    Keynote lecture #2: The Impact of Microbiota on Host Diseases and Drugs Using Estonian Microbiome Cohort Data by Prof. Elin Org

    What is the microbiome? How does it affect human health and mental health?

    New keynote now live!

    Learn about the Gut-Brain Connection and the association between microbiome and diseases.

    We invited Dr. Elin Org, associate professor at the University of Tartu as keynote speaker to talk about The Impact of Microbiota on Host Diseases and Drugs Using Estonian Microbiome Cohort Data.

  • 10 December 2023

    How can we improve the management of individuals with attention deficit hyperactivity disorders and co-occurring cardiometabolic disease?

    Read in, as Prof. Dr. Henrik Larsson, coordinator of the TIMESPAN project, discusses the questions

    • Why improve the management of cardiometabolic disease in ADHD?
    • Which knowledgegaps need to be addressed?

    Click here to read the full review article.

  • 30 November 2023

    Masterclass #3: ADHD Biomarkers by Prof. Dr. Jan Buitelaar

    Prof. Dr. Jan Buitelaar, professor of child and adolescent psychiatry at Radboud University Medical Center, provides a thorough overview of current research on ADHD biomarkers in this masterclass. He delves into several reviews and meta-analytical papers on different types of biomarkers, and highlights the principles and validation processes of biomarkers in general. The session is enriched with insightful examples from biomarker research, offering a deep and engaging exploration of this intricate field.

    Watch the masterclass in our masterclass section or directly on YouTube.

  • 27 November 2023

    New paper on psychiatric comorbidities in women with and without ADHD in Iceland

    A cross-sectional analysis of the nationwide, all-female, population-based SAGA Cohort Study has been published in BMC Medicine. Congratulations to the team!

    Conclusion: ADHD is overrepresented among women with cardiometabolic conditions and contributes to other psychiatric comorbidities.

    Click here to read full article.

  • 27 November 2023

    First multinational study from TIMESPAN published

    “Early medication discontinuation is common in ADHD across countries, which can represent a major barrier to positive treatment outcomes.”

    The first multinational study published in Lancet Psychiatry reveals key insights into ADHD medication discontinuation covering 9 countries and regions. Our research shows early discontinuation is common, particularly in young adults. Read full article here.

    Congratulations to the team!

  • 22 November 2023

    New paper from our TIMESPAN colleagues using Swedish register data

    Is long-term use of attention-deficit/hyperactivity disorder (ADHD) medication associated with an increased risk of cardiovascular disease (CVD)?

    This nationwide study found long-term exposure to ADHD medication was associated with increased risk of cardiovascular disease; therefore, the potential risks and benefits of long-term ADHD medication use should be carefully weighed.

    Click here to read full article.

  • 10 November 2023

    ART-CARMA study reaches two big milestones

    In November, we reached two big milestones in WP5 – the first ART-CARMA study participant has finished their 12-month remote-monitoring period and we are halfway through the recruitment now (150 participants enrolled). Thank you to all of our participants for your valuable input and to the data collection teams in London and Barcelona!

  • 2 November 2023

    TIMESPAN at ODISSEI conference 2023

    Last week, Catharina Hartman of Partner UMCG presented during the ODISSEI conference: “The association between Attention Deficit Hyperactivity Disorder and treatment discontinuation for Type 2 Diabetes Mellitus: research based on a nationwide population-based cohort study in the Netherlands”

    Yiran Li, also of UMCG, presented her poster with the title “Cardiometabolic diseases of people with Autism Spectrum Disorder: a nationwide population-based cohort study in the Netherlands”.

  • 24 October 2023

    TIMESPAN Podcast: Perspectives of people with ADHD. Andrea Bilbow, OBE (ep 1)

    Welcome to the TIMESPAN Podcast! A format that gives a stage to different perspectives of people with ADHD. In the very first episode, Andrea Bilbow (OBE), shares her personal ADHD journey. Andrea Bilbow is founder and CEO at ADDISS the UK National Attention Deficit Disorder Information and Support Service, which she founded in 1995.

    Citing her own words, Andrea is the poster girl for TIMESPAN, as our main objective is to advance the management of adult attention deficit hyperactivity disorder and co-occurring cardiometabolic disease. Emerging evidence points at substantial comorbidity and shared genetics between adult ADHD and cardiometabolic diseases i.e., Obesity, Type 2 Diabetes and cardiovascular disease (CVD). However, screening, diagnosis and treatment guidelines for ADHD patients with these diseases do not exist. TIMESPAN builds on real-world data from daily clinical practice, but will also collect new detailed data through Remote Measurement Technology (RMT) to allow for improved identification of ADHD patients at risk for cardiometabolic outcomes and improved multidisciplinary and personalized treatment approaches. TIMESPAN is an EU-funded research project led by international recognised leaders working together on an interdisciplinary basis, consisting of clinicians, epidemiologists, biostatisticians, geneticists and artificial intelligence computer scientists.

  • 27 September 2023

    TIMESPAN members receive Kramer-Pollnow Prize!

    Last week, our TIMESPAN members Kenneth Man (from UCL in London) and Zheng Chang (from Karolinska Institutet in Stockholm) were awarded the Kramer-Pollnow Prize for scientific excellence in the research on ADHD!

    Congratulations!

    The prize was presented at this year’s EUNETHYDIS members meeting in Montpellier, France.

    The Kramer-Pollnow Prize is awarded every two years for scientific excellence in research in child and adolescent psychiatry.

    Kramer-Pollnow Prize awardees Kenneth Man, PhD from UCL, Zheng Chang, PhD, from KI
    Photo ©EUNETHYDIS
  • 6 September 2023

    Keynote lecture #1: Epidemiological conditions of cardiovascular diseases by Pontus Andell, MD, PhD

    Pontus Andell, MD, PhD, associate professor at Karolinska Institutet and resident cardiologist at Karolinska University Hospital in Stockholm, Sweden, held the very first keynote lecture titled “Epidemiological conditions of cardiovascular diseases” during the General Assembly Meeting of TIMESPAN in Stockholm in May 2022.

    Learn more about which cardiovascular diseases are most relevant in ADHD, the burden of cardiovascular diseases in general, and how we can use registry-based data to study CVDs in the keynote lecture.

  • 2 August 2023

    Masterclass #2: What can family data tell us about unmeasured confounding? by Ralf Kuja-Halkola, PhD

    Ralf Kuja-Halkola, PhD, researcher and statistician at Karolinska Institutet in Stockholm, Sweden, gave a masterclass titled “What can family data tell us about unmeasured confounding?” during the General Assembly Meeting of TIMESPAN in Stockholm in May 2022.

    Learn more about directed acyclic graphs and how to use them to make assumptions about associations in his masterclass.

  • 22 July 2023

    World Brain Day 2023

    Every year, 22nd July marks World Brain Day, an awareness day launched by World Federation of Neurology. Even though the 2023 theme is “Brain Health and Disability: Leave No One Behind”, it is also important to talk about ADHD brains!

    ADHD is a neurodevelopmental condition with traits and behaviours stemming from a different brain development in key stages of brain development.

    Research has identified several potential disparities in the brains of individuals with ADHD compared to those without the condition. However, the precise significance of these variances remains uncertain.

    https://www.additudemag.com/category/adhd-add/adhd-brain/ is a great resource for understanding the neuroscience behind ADHD.

    TIMESPAN aims to improve not only the assessment of the risks involved for patients, but also to review and improve already existing treatments for patients with ADHD who also have cardiometabolic disease.

  • 12 May 2023

    Meet TIMESPAN members at 9th World Congress on ADHD

    We’re excited to share that members of our consortium will present at the 9th World Congress on ADHD from 18 – 21 May, 2023 in Amsterdam, NL.

    18.05.2023:

    3:00 – 4:30 pm CET, room G107

    Dr. Zheng Chang from Karolinska, Sweden, and Prof. Ditte Demontis from Aarhus Uni, Denmark will chair the Hot topic “Advancing the understanding of ADHD treatment discontinuity using real-world data”

    Sessions include:

    • ADHD treatment discontinuation across the lifespan: A multi-national study (by Zheng Chang)
    • Adherence of ADHD medication and pharmacological treatment for cardiovascular disease (by Zheng Chang)
    • Remote measurement technology data on real-world treatment response to ADHD medication in adults with ADHD following initiation of medication (by Hayley Denyer, Kings College London)
    • Genetic loci and polygenic architecture of simulant ADHD medication discontinuation (by Prof. Ditte Demontis)

    3:00 – 4:30 pm CET, room G109

    Dr Le Zhang, will present “ADHD medications and long-term risk of cardiovascular diseases: A nationwide nested case-control study in Sweden” at Young Scientists´ Session I.

    19.05.2023:

    2:00 – 3:30 pm CET, Onyx Lounge

    The poster session “Comorbidity: adults” is chaired by TIMESPAN partner Prof. Josep Antoni Ramos Quiroga (from Fundacio Hospital Universitari Vall D’Hebron).

    In this session, Unnur Jakobsdottir Smari, of TIMESPAN partner University of Iceland, will be presenting her poster: “Anxiety and mood disorders in women with cardiometabolic conditions with and without ADHD: A population-based cross sectional study”.

    Additionally, Nina Nielsen, of our partner Aarhus University, will present her poster, titled “Association between ADHD and initiation of a lipid-lowering drug in adults: A nationwide study”.

    20.05.2023:

    3:30 – 5:00 pm CET, room G102-G103

    Prof. Jonna Kuntsi of Kings College London will be chairing the Hot Topic Session: ‘What is new in digital psychiatry in ADHD?’ and providing a talk in this session ‘ADHD Remote Technology (ART) research programme: from current research towards future clinical application’

  • 17 April 2023

    Successful meeting: TIMESPAN’s third General Assembly

    TIMESPAN’s 3rd General Assembly Meeting took place in Tallinn, Estonia from 12 – 14 April, 2023. The meeting started with a masterclass given by Prof. Jan Buitelaar from Radboud University Medical Center and a keynote lecture by Dr. Elin Org from the University of Tartu.

    During the two main meeting days, work package leaders and members have presented and discussed their scientific data and the overall progress of their work. Thanks to invaluable discussions, the consortium is now full of beans for the months to come.

  • 28 November 2022

    TIMESPAN´s first ECS Journal Club

    The 1st TIMESPAN ECS Journal Club, started with Hayley Denyer´s brilliant presentation about the ADHD Remote Technology (‘ART’) pilot study. Thanks to all involved for livening up the discussion and for sharing knowledge!

  • 9 November 2022

    Intensive and successful 4th SC-Meeting

    What an intensive 4th SC-Meeting! We were delighted meeting all TIMESPAN partners again and hear about #TIMESPAN ´s big #progress on #management of #chronic#cardiometabolic disease and #treatment discontinuity in #adult#ADHD patients. Let´s keep up the amazing work!

    💪

  • 24 October 2022

    TIMESPAN @ EASO: Webinar on ADHD and Obesity

    Don´t miss the EASOCOMs Webinar: ADHD and Obesity on 25th October 2022!

    When? 12.30-14.00 CEST

    TIMESPAN Prof Henrik Larsson and Prof Dr J. Antoni Ramos presenting ADHD101
    • Professor Henrik Larsson will present the register-based studies from Sweden exploring causes and consequences of obesity in ADHD
    • Professor Dr J. Antoni Ramos-Quiroga will present ADHD across lifespan

  • 19 August 2022

    TIMESPAN´s Rubik´s Cube out now

    … as a digital intro version for all TIMESPAN video products..🎥

    More Details...
  • 7 May 2022

    TIMESPAN webinar at ADHD Europe

    TIMESPAN coordinator Prof. Henrik Larsson from the Örebro University in Sweden gives a short webinar about the TIMESPAN project at ADHD Europe.

    👉Watch the whole webinar here.

  • 1 April 2022

    Happy Birthday #1year

    Today we celebrate #oneyear of successful and amazing #work within the TIMESPAN project. Thanks to all TIMESPAN partners for all your efforts you made so far! Let’s keep on going!

    #ADHD#adhdtwitter#ADHDlife#wearables#1year#eu#H2020

  • 24 February 2022

    TIMESPAN Patient Brochure

    In collaboration with ADHD Europe our new brochure for patients is available as web and print version with the most important facts of TIMESPAN and how the ART-CARMA research contributes to a healthier future for ADHD patients.

  • 30 November 2021

    2nd SC Meeting

    Our 2nd SC meeting was held (once again) remote on 29 – 30 November 2021. Thank you all for your interesting updates as well as the great brainstorming sessions during the 2nd SC meeting! @orebrouni@karolinskainst@AarhusUni@UiB@researchumcg@vallhebron@KingsIoPPN@concentris_EU@EASOobesity@UpstateNews@empatica@hkumed#H2020#ADHD

  • 3 October 2021

    TIMESPAN at the 34th ECNP Congress

    📢 TIMESPAN was represented today at ECNP by @IsabellBrikell. She talked about somatic health in ADHD, including results for several of the cardiometabolicdisorder we are looking into in TIMESPAN.

    ⏲️ 13:15-14:35 WEST
    🏛️ Auditorium I of the #Lisbon #Congress #Venue

  • 24 September 2021

    TIMESPAN Project Brochure

    You can now access a web and a print version of the project’s info brochure with the most important facts of TIMESPAN and how the ART-CARMA research contributes to a healthier future for ADHD patients.

  • 18 May 2021

    KICK-OFF TIMESPAN meeting

    The EU-funded research project TIMESPAN kicked off on May 18th – 19th 2021. The meeting was held remotely and although being held virtually it was full of vivid discussions as well as social interaction. 17 partners from all over the world joined forced evaluate the next steps that has to be taken in TIMESPAN. One of the main tasks was data harmonization as well as data access, definition of treatment discontinuity, and joined dissemination. All TIMESPAN scientific as well as ad hoc advisors also joined the meeting and provided a very valuable feedback on the project start.

  • 1 April 2021

    KICK-OFF TIMESPAN project

    No April Fool’s joke, but the start of an exciting journey! Today, April 1st 2021, the 5 year-long EU-funded TIMESPAN project kicks off! 17 partners from academia, industry, and patient advocacy join forces in fostering improvements in clinical management of adults with #ADHD and co-occurring cardiometabolic disease.

    Various national guidelines on cardiometabolic disease already highlight the importance of concurrent psychiatric disorders, but there is a lack of knowledge around ADHD. TIMESPAN strives to improve clinical outcomes, as well as Quality Of Life in adult ADHD patients with cardiometabolic disease.

Events

  • 16 April 2024

    TIMESPAN’s 4th General Assembly Meeting

    🌟 Reflecting on an important event for TIMESPAN! 🧠
    Last week, we convened for our fourth General Assembly Meeting in Copenhagen, Denmark, where we engaged in in-depth discussions covering our different work packages.
    A highlight ✨ was our posterwalk, where TIMESPAN’s Early Career Researchers presented their work and received valuable feedback.

    It was an inspiring meeting filled with insightful discussions and strategic planning for the future of our project.

    The dedication and collaboration of our international team continues to drive our project forward.

    A huge thank you to everyone who participated and contributed to making this meeting a success! Onward and upward! 💪

  • 10 April 2024

    TIMESPAN’s 4th GA meeting

    We look forward to meeting the consortium members April 10 – 12, 2024.

  • 4 April 2024

    Upcoming: TIMESPAN’s 4th GA Meeting

    Packed your suitcases and prepared all slides, yet? It’s less than a week until the TIMESPAN consortium meets again in-person, and for our colleagues who can’t make it to beautiful Copenhagen, there will be a hybrid option. During our 4th General Assembly Meeting, we’ll be discussing the project’s progress, its achievements so far, and plan ahead for the year to come.

  • 9 November 2023

    TIMESPAN 6th SC meeting

    Our 6th Steering Committee meeting will be held remotely on November 9th, 2023. During this full-day meeting, we look forward to hearing about the work packages’ progress, productive discussions and expertise sharing.

  • 7 October 2023

    TIMESPAN at ECNP2023

    The European College of Neuropsychopharmacology (ECNP), an independent scientific association dedicated to the science and treatment of disorders of the brain, again hosts its annual congress. We’re delighted that members of TIMESPAN will be attending the 36th edition of the ECNP congress.
    📅 7 – 10 October 2023
    📍 Barcelona, Spain

    More info on the congress here.

  • 12 May 2023

    Meet TIMESPAN members at 9th World Congress on ADHD

    We’re excited to share that members of our consortium will present at the 9th World Congress on ADHD from 18 – 21 May, 2023 in Amsterdam, NL.

    18.05.2023:

    3:00 – 4:30 pm CET, room G107

    Dr. Zheng Chang from Karolinska, Sweden, and Prof. Ditte Demontis from Aarhus Uni, Denmark will chair the Hot topic “Advancing the understanding of ADHD treatment discontinuity using real-world data”

    Sessions include:

    • ADHD treatment discontinuation across the lifespan: A multi-national study (by Zheng Chang)
    • Adherence of ADHD medication and pharmacological treatment for cardiovascular disease (by Zheng Chang)
    • Remote measurement technology data on real-world treatment response to ADHD medication in adults with ADHD following initiation of medication (by Hayley Denyer, Kings College London)
    • Genetic loci and polygenic architecture of simulant ADHD medication discontinuation (by Prof. Ditte Demontis)

    3:00 – 4:30 pm CET, room G109

    Dr Le Zhang, will present “ADHD medications and long-term risk of cardiovascular diseases: A nationwide nested case-control study in Sweden” at Young Scientists´ Session I.

    19.05.2023:

    2:00 – 3:30 pm CET, Onyx Lounge

    The poster session “Comorbidity: adults” is chaired by TIMESPAN partner Prof. Josep Antoni Ramos Quiroga (from Fundacio Hospital Universitari Vall D’Hebron).

    In this session, Unnur Jakobsdottir Smari, of TIMESPAN partner University of Iceland, will be presenting her poster: “Anxiety and mood disorders in women with cardiometabolic conditions with and without ADHD: A population-based cross sectional study”.

    Additionally, Nina Nielsen, of our partner Aarhus University, will present her poster, titled “Association between ADHD and initiation of a lipid-lowering drug in adults: A nationwide study”.

    20.05.2023:

    3:30 – 5:00 pm CET, room G102-G103

    Prof. Jonna Kuntsi of Kings College London will be chairing the Hot Topic Session: ‘What is new in digital psychiatry in ADHD?’ and providing a talk in this session ‘ADHD Remote Technology (ART) research programme: from current research towards future clinical application’

  • 17 April 2023

    Successful meeting: TIMESPAN’s third General Assembly

    TIMESPAN’s 3rd General Assembly Meeting took place in Tallinn, Estonia from 12 – 14 April, 2023. The meeting started with a masterclass given by Prof. Jan Buitelaar from Radboud University Medical Center and a keynote lecture by Dr. Elin Org from the University of Tartu.

    During the two main meeting days, work package leaders and members have presented and discussed their scientific data and the overall progress of their work. Thanks to invaluable discussions, the consortium is now full of beans for the months to come.

  • 28 November 2022

    TIMESPAN´s first ECS Journal Club

    The 1st TIMESPAN ECS Journal Club, started with Hayley Denyer´s brilliant presentation about the ADHD Remote Technology (‘ART’) pilot study. Thanks to all involved for livening up the discussion and for sharing knowledge!

  • 24 October 2022

    TIMESPAN @ EASO: Webinar on ADHD and Obesity

    Don´t miss the EASOCOMs Webinar: ADHD and Obesity on 25th October 2022!

    When? 12.30-14.00 CEST

    TIMESPAN Prof Henrik Larsson and Prof Dr J. Antoni Ramos presenting ADHD101
    • Professor Henrik Larsson will present the register-based studies from Sweden exploring causes and consequences of obesity in ADHD
    • Professor Dr J. Antoni Ramos-Quiroga will present ADHD across lifespan

  • 23 June 2021

    ART-CARMA study

    Focus group is currently established. The KCL team around Jonna Kuntsi is currently establishing a focus group who should be involved in the discussions on how to incorporate remote technology in the ADHD assessment and initial period of starting medication. In case you are interested in the participation please get in contact with: Hayley Denyer